Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8896553 | 0.80 | GLA (0.37) | HDAC8 | |
| SCHEMBL7589150 | 0.74 | — | — | |
| SCHEMBL455667 | 0.72 | — | — | |
| SCHEMBL1776424 | 0.70 | TRPA1 (0.35) | — | |
| SCHEMBL2189095 | 0.70 | HDAC8 (0.34) | HDAC8 | |
| SCHEMBL677008 | 0.70 | LMNA (0.37) | HDAC8 | |
| SCHEMBL10612043 | 0.68 | ESR1 (0.31) | — | |
| SCHEMBL7864443 | 0.68 | GABRA1 (0.32) | — | |
| SCHEMBL207542 | 0.68 | GABRA1 (0.32) | — | |
| SCHEMBL207047 | 0.68 | CYP1A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458967-B1 | REACTING ACETYLENE COMPOUNDS TO FORM ENOL ETHER; REACTING WITH SULFUR OR SELENIUM OR TELLURIUM COMPOUND TO FORM DYE PRODUCT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-10-01 | — | — | US | disclosed |
| US-20020022723-A1 | Method for preparation of an intermediate dye product | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE STATE UNIVERSITY OF NEW YORK AT BUFFALO | 2002-02-21 | — | — | US | disclosed |
| WO-2002000642-A1 | METHOD FOR PREPARATION OF AN INTERMEDIATE DYE PRODUCT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-1071660-A1 | N-SULPHONYL AND N-SULPHINYL PHENYLGLYCINAMIDE | Novartis AG (CH) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999043644-A1 | N-SULPHONYL AND N-SULPHINYL PHENYLGLYCINAMIDE___________________ | NOVARTIS AG (CH) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022723-A1 | Method for preparation of an intermediate dye product | SRD5A1, SRD5A2, RER1 | HDAC8 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.